Repositioning of clinically approved drug Bazi Bushen capsule for treatment of Aizheimer's disease using network pharmacology approach and in vitro experimental validation

Tongxing Wang; Meng Chen; Huixin Li; Guoyuan Ding; Yanfei Song; Bin Hou; Bing Yao; Zhixin Wang; Yunlong Hou; Junqing Liang; Cong Wei; Zhenhua Jia

doi:10.1016/j.heliyon.2023.e17603

Repositioning of clinically approved drug Bazi Bushen capsule for treatment of Aizheimer's disease using network pharmacology approach and in vitro experimental validation

Heliyon. 2023 Jun 27;9(7):e17603. doi: 10.1016/j.heliyon.2023.e17603. eCollection 2023 Jul.

Authors

Tongxing Wang^{1

2}, Meng Chen^{1

2}, Huixin Li^{1

2}, Guoyuan Ding^{1

2}, Yanfei Song^{1

2}, Bin Hou^{1

2}, Bing Yao^{1

2}, Zhixin Wang^{1

2}, Yunlong Hou^{1

2}, Junqing Liang^{1

2}, Cong Wei^{1

2

3}, Zhenhua Jia^{1

2

3}

Affiliations

¹ National Key Laboratory of Collateral Disease Research and Innovative Chinese Medicine, Shijiazhuang, 050035, PR China.
² Hebei Yiling Pharmaceutical Research Institute, Key Laboratory of State Administration of TCM (Cardio-Cerebral Vessel Collateral Diseases), Shijiazhuang, 050035, PR China.
³ Key Disciplines of State Administration of TCM for Collateral Disease, Shijiazhuang, 050035, PR China.

Abstract

Aims: To explore the new indications and key mechanism of Bazi Bushen capsule (BZBS) by network pharmacology and in vitro experiment.

Methods: The ingredients library of BZBS was constructed by retrieving multiple TCM databases. The potential target profiles of the components were predicted by target prediction algorithms based on different principles, and validated by using known activity data. The target spectrum of BZBS with high reliability was screened by considering the source of the targets and the node degree in compound-target (C-T) network. Subsequently, new indications for BZBS were predicted by disease ontology (DO) enrichment analysis and initially validated by GO and KEGG pathway enrichment analysis. Furthermore, the target sets of BZBS acting on AD signaling pathway were identified by intersection analysis. Based on STRING database, the PPI network of target was constructed and their node degree was calculated. Two Alzheimer's disease (AD) cell models, BV-2 and SH-SY5Y, were used to preliminarily verify the anti-AD efficacy and mechanism of BZBS in vitro.

Results: In total, 1499 non-repeated ingredients were obtained from 16 herbs in BZBS formula, and 1320 BZBS targets with high confidence were predicted. Disease enrichment results strongly suggested that BZBS formula has the potential to be used in the treatment of AD. GO and KEGG enrichment results provide a preliminary verification of this point. Among them, 113 functional targets of BZBS belong to AD pathway. A PPI network containing 113 functional targets and 1051 edges for the treatment of AD was constructed. In vitro experiments showed that BZBS could significantly reduce the release of TNF-α and IL-6 and the expression of COX-2 and PSEN1 in Aβ_25-35-induced BV-2 cells, which may be related to the regulation of ERK_1/2/NF-κB signaling pathway. BZBS reduced the apoptosis rate of Aβ_25-35 induced SH-SY5Y cells, significantly increased mitochondrial membrane potential, reduced the expression of Caspase3 active fragment and PSEN1, and increased the expression of IDE. This may be related to the regulation of GSK-3β/β-catenin signaling pathway.

Conclusions: BZBS formula has a potential use in the treatment of AD, which is achieved through regulation of ERK_1/2, NF-κB signaling pathways, and GSK-3β/β-catenin signaling pathway. Furthermore, the network pharmacology technology is a feasible drug repurposing strategy to reposition new clinical use of approved TCM and explore the mechanism of action. The study lays a foundation for the subsequent in-depth study of BZBS in the treatment of AD and provides a basis for its application in the clinical treatment of AD.

Keywords: Aizheimer's disease; Bazi Bushen capsule; Drug repositioning; Mechanism of action; Network pharmacology; Network targets.